针对HDAC6作为抗癌药物的选择性抑制剂的最近发展:结构,功能和设计
Jie Peng1, Fei Xie2, Pengxia Qin1
1Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, PR China.
Bioorganic chemistry
|May 27, 2023
概括
希斯脱乙酶6 (HDAC6) 通过非希斯基质调节癌细胞的生长. 选择性HDAC6抑制剂对于开发具有较少副作用的向癌症治疗至关重要.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- HDAC6是一种细胞突变蛋白,通过非歇斯顿基质 (如α-tubulin,cortactin,HSP90,PD-1和PD-L1.1) 调节细胞生长.
- 这些基质对于癌症的扩散,入侵,免疫逃脱和血管生成至关重要.
- 目前的HDAC抑制剂是非选择性的泛抑制剂,导致显著的副作用.
研究的目的:
- 审查HDAC6在癌症中的作用.
- 讨论设计选择性HDAC6抑制剂用于癌症治疗的最新策略.
主要方法:
- 对HDAC6和癌症研究的文献综述.
- 对HDAC6抑制剂的设计策略的分析.
主要成果:
- HDAC6在各种癌症特征中发挥着重要作用.
- 选择性HDAC6抑制剂的开发是一个有前途的治疗策略.
- 最近的研究集中在针对性抑制的新型分子设计上.
结论:
- HDAC6是癌症的关键治疗点.
- 选择性HDAC6抑制为改善癌症治疗提供了一个有希望的途径,降低了毒性.
相关概念视频
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Structure-Activity Relationships and Drug Design
801
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
801
Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K


